You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Baseline infecting intra-abdominal pathogens and uropathogens (MITT/cIAI population and mMITT/cUTI population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

Pathogen,a n (%) cIAI cUTI
Diabetes n = 65 No diabetes n = 741 Diabetes n = 133 No diabetes n = 667
Gram-negative aerobes 46 (70.8) 613 (82.7) 127 (95.5) 637 (95.5)
 Enterobacteriaceae 45 (69.2) 577 (77.9) 126 (94.7) 613 (91.9)
   Escherichia coli 37 (56.9) 488 (65.9) 99 (74.4) 530 (79.5)
   Klebsiella pneumoniae 0 (0.0) 70 (9.4) 14 (10.5) 44 (6.6)
Pseudomonas aeruginosa 0 (0.0) 68 (9.2) 1 (0.8) 22 (3.3)
Gram-positive aerobes 38 (58.5) 406 (54.8) 6 (4.5) 42 (6.3)
Enterococcus faecalis 16 (24.6) 79 (10.7) 4 (3.0) 34 (5.1)
E. faecium 0 (0.0) 74 (10.0) 0 (0.0) 5 (0.7)
Staphylococcus aureus 0 (0.0) 27 (3.6) 2 (1.5) 4 (0.6)
Gram-negative anaerobes 24 (36.9) 267 (36.0) 0 (0.0) NA
Bacteroides spp 23 (35.4) 228 (30.8) 0 (0.0) NA
Gram-positive anaerobes 7 (10.8) 92 (12.4) 0 (0.0) NA
  1. cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, MITT microbiologic intention-to-treat, mMITT microbiologic modified intention-to-treat, NA, not applicable
  2. aPatients could have had multiple infecting pathogens at baseline